Skip to main content

Table 2 Meta-analysis for the hsa-miR-499 rs3746444 T > C polymorphism and cancer risk

From: Meta-analysis of Hsa-mir-499 polymorphism (rs3746444) for cancer risk: evidence from 31 case-control studies

Genetic model

N a

C vs T

TC vs TT

CC vs TT

TC/CC vs TT (dominant)

CC vs TC/TT (recessive)

Pooled OR [95% CI]

P h b

P c

Pooled OR [95% CI]

P h b

P c

Pooled OR [95% CI]

P h b

P c

Pooled OR [95% CI]

P h b

P c

Pooled OR [95% CI]

P h b

P c

Total

31

1.08 (0.99-1.17)

<0.00001

0.08

1.11 (1.00-1.23)

<0.00001

0.04

1.02 (0.85-1.22)

0.002

0.85

1.11 (1.01-1.23)

<0.00001

0.03

0.98 (0.81-1.17)

0.001

0.79

Ethnicities

Asian

28

1.10 (1.00-1.21)

<0.00001

0.06

1.14 (1.02-1.27)

<0.00001

0.02

1.02 (0.82-1.27)

0.0009

0.86

1.14 (1.02-1.27)

<0.00001

0.02

0.97 (0.78-1.20)

0.0004

0.76

Chinese

16

1.11 (0.95-1.28)

<0.00001

0.18

1.18 (1.02-1.35)

0.0002

0.02

0.92 (0.65-1.32)

0.001

0.66

1.15 (0.99--1.34)

<0.00001

0.07

0.89 (0.63-1.24)

0.004

0.48

Indian

4

1.03 (0.87-1.23)

0.19

0.70

1.26 (0.84-1.88)

0.005

0.26

0.91 (0.63-1.31)

0.33

0.62

1.18 (0.84-1.65)

0.02

0.34

0.79 (0.52-1.20)

0.18

0.27

Korean

3

0.94 (0.78-1.13)

0.26

0.49

0.89 (0.72-1.11)

0.27

0.31

0.89 (0.54-1.48)

0.62

0.66

0.93 (0.75-1.15)

0.25

0.48

0.95 (0.58-1.57)

0.65

0.84

Iranians

2

1.57 (1.23-2.01)

0.34

0.0003

0.99 (0.68-1.45)

0.54

0.97

2.23 (1.42-3.51)

0.54

0.0005

1.38 (1.00-1.91)

0.78

0.05

2.23 (1.44-3.45)

0.41

0.0003

Others

3

1.11 (0.96-1.29)

0.88

0.16

1.22 (0.77-1.95)

0.04

0.40

1.24 (0.89-1.73)

0.67

0.20

1.19 (0.86-1.63)

0.16

0.30

1.13 (0.77-1.67)

0.21

0.53

Caucasian

3

0.95 (0.88-1.04)

0.39

0.28

0.93 (0.77-1.12)

0.12

0.44

0.96 (0.76-1.20)

0.97

0.71

0.93 (0.80-1.09)

0.19

0.36

0.98 (0.78-1.22)

0.87

0.83

Cancer type

Liver cancer

8

1.12 (0.85-1.54)

<0.00001

0.46

1.14 (0.85-1.54)

0.0002

0.38

1.03 (0.55-1.92)

0.0005

0.93

1.15 (0.82-1.61)

<0.00001

0.43

0.99 (0.57-1.71)

0.002

0.97

Breast cancer

4

1.25 (0.99-1.57)

0.0002

0.06

1.15 (0.91-1.45)

0.04

0.24

1.43 (0.87-2.34)

0.009

0.16

1.24 (0.99-1.55)

0.03

0.06

1.30 (0.75-2.24)

0.002

0.35

Gastric cancer

4

1.03 (0.90-1.18)

0.49

0.66

0.98 (0.83-1.15)

0.54

0.79

1.21 (0.84-1.75)

0.66

0.31

1.01 (0.86-1.17)

0.53

0.95

1.22 (0.85-1.76)

0.66

0.28

Colorectal cancer

3

0.96 (0.82-1.13)

0.42

0.62

1.05 (0.87-1.26)

0.96

0.64

0.61 (0.23-1.62)

0.09

0.32

1.00 (0.84-1.20)

0.73

0.99

0.61 (0.23-1.58)

0.10

0.31

Lung cancer

2

0.96 (0.82-1.13)

0.83

0.64

0.98 (0.81-1.18)

0.60

0.84

0.88 (0.54-1.44)

0.92

0.61

0.97 (0.81-1.16)

0.68

0.74

0.87 (0.54-1.42)

0.84

0.59

Esophageal cancer

2

0.80 (0.66-0.98)

0.75

0.03

0.81 (0.63-1.04)

0.80

0.10

0.60 (0.33-1.08)

0.88

0.09

0.79 (0.62-1.00)

0.83

0.05

0.64 (0.36-1.14)

0.93

0.13

Others

8

1.11 (0.97-1.26)

0.05

0.13

1.27 (0.98-1.65)

<0.0001

0.07

0.99 (0.79-1.25)

0.80

0.93

1.12 (0.98-1.53)

0.0004

0.07

0.91 (0.72-1.16)

0.37

0.46

  1. aNumber of comparisons.
  2. bP h value of Q-test for heterogeneity test. Random-effects model was used when P value for heterogeneity test <0.1; otherwise, fix-effects model was used.
  3. cP value for significance, the cutoff point of statistical significance was set at p < 0.05, which was shown in boldface.
Back to article page

BMC Medical Genetics

ISSN: 1471-2350

Contact us